Immunorepertoire Mapping

By combining the last 30 years of improvements in monoclonal antibody development, multiplex PCR technology, high-throughput sequencing and bioinformatic, our new immunorepertoire mapping technology has successfully overcome past challenges of studying the immunorepertoire. We are currently using this technology to analyze the immunorepertoires of autoimmune diseases such as systemic lupus erythematosus and various cancers – including colon cancer, breast cancer, lung cancer and leukemias – through an international collaboration called R10K, partnered with HudsonAlpha. The project will sequence 10,000 samples and study biomarkers for 100 diseases. By studying the immunorepertoire, we hope to uncover possible disease mechanisms, identify new biomarkers and develop new therapeutics.  


Color Skin